睿知中国医院研究地图
候选清单

哈尔滨哈尔滨医科大学

哈尔滨医科大学附属第一医院

First Affiliated Hospital of Harbin Medical University

在本站收录的 61 种疾病中,这家医院列在其中 23 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。

这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。

这家医院的官网还没有核对。

联系这家医院

哈尔滨医科大学附属第一医院的研究

选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。

只包括本站收录的 61 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出

  1. 肝细胞癌Hepatocellular carcinoma31 篇牵头论文
  2. 肺癌Lung cancer25 篇牵头论文
  3. 胰腺癌Pancreatic cancer23 篇牵头论文
  4. 乳腺癌Breast cancer23 篇牵头论文
  5. 胶质瘤Glioma35 篇牵头论文
  6. 肝母细胞瘤Hepatoblastoma0 篇牵头论文
  7. 视网膜母细胞瘤Retinoblastoma2 篇牵头论文
  8. 骨肉瘤Osteosarcoma21 篇牵头论文
  9. 胃肠道间质瘤Gastrointestinal stromal tumour0 篇牵头论文
  10. 神经母细胞瘤Neuroblastoma3 篇牵头论文
  11. 尤文肉瘤Ewing sarcoma1 篇牵头论文
  12. 多发性骨髓瘤Multiple myeloma4 篇牵头论文
  13. B 细胞急性淋巴细胞白血病B-cell acute lymphoblastic leukaemia2 篇牵头论文
  14. 淋巴瘤Lymphoma1 篇牵头论文牵头 1 项开放试验
  15. 血栓性血小板减少性紫癜Thrombotic thrombocytopenic purpura1 篇牵头论文
  16. 烟雾病Moyamoya disease2 篇牵头论文
  17. 冠心病Coronary heart disease8 篇牵头论文
  18. 脊柱侧弯Scoliosis2 篇牵头论文
  19. 特发性肺纤维化Idiopathic pulmonary fibrosis2 篇牵头论文
  20. 肌萎缩侧索硬化症Amyotrophic lateral sclerosis11 篇牵头论文
  21. 白塞病Behçet disease1 篇牵头论文
  22. IgA 肾病IgA nephropathy2 篇牵头论文
  23. 先天性巨结肠Hirschsprung disease1 篇牵头论文

未列出的收录疾病:鼻咽癌、食管鳞状细胞癌、胃癌、脊索瘤、再生障碍性贫血、噬血细胞性淋巴组织细胞增生症、β 地中海贫血、血友病 A、非典型溶血性尿毒症综合征、范可尼贫血、视神经脊髓炎谱系疾病、IgG4相关性疾病、重症肌无力、肝豆状核变性、胆道闭锁、先天性心脏病、抗 NMDA 受体脑炎、大动脉炎、肝包虫病、肺淋巴管平滑肌瘤病、脊髓性肌萎缩症、法布雷病、庞贝病、杜氏肌营养不良、Alport 综合征、戈谢病、尼曼-匹克病 C 型、成骨不全症、原发性胆汁性胆管炎、原发性硬化性胆管炎、先天性膈疝、遗传性大疱性表皮松解症、遗传性血管性水肿、家族性腺瘤性息肉病、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。

癌症

肝细胞癌

Hepatocellular carcinoma

2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 31 篇,占 0.2%。

牵头论文
31
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 6620212022: 8820222023: 7720232024: 7720242025: 332025

哈尔滨有 4 家医院列在肝细胞癌下全国有 194 家医院列在肝细胞癌下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的肝细胞癌开放试验。

这些数字背后的记录
研究主题复发与预后免疫与靶向药物影像、人工智能与早期发现
论文中的科室普外/肝胆胰外科影像/核医学科病理/检验科

这些论文过半是实验室或动物研究。

牵头的论文31
  1. A STT3A-dependent PD-L1 glycosylation modification mediated by GMPS drives tumor immune evasion in hepatocellular carcinoma.2025Cell death and differentiation免费全文
  2. Periodontitis and Hepatocellular Carcinoma: A Two-Sample Mendelian Randomisation Study.2025International dental journal免费全文
  3. Melanin@PLGA/Nuciferine Nanoparticles for Enhanced Photothermal Therapy of Hepatocellular Carcinoma by Promoting Autophagy.2025International journal of nanomedicine免费全文
  4. Hepatocellular Carcinoma LINC01116 Outcompetes T Cells for Linoleic Acid and Accelerates Tumor Progression.2024Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  5. DEAD-Box Helicase 17 circRNA (circDDX17) Reduces Sorafenib Resistance and Tumorigenesis in Hepatocellular Carcinoma.2024Digestive diseases and sciences
  6. RGS19 activates the MYH9/β-catenin/c-Myc positive feedback loop in hepatocellular carcinoma.2024Experimental & molecular medicine免费全文
  7. FBW7-Mediated Degradation of CHD3 Suppresses Hepatocellular Carcinoma Metastasis and Stemness to Enhance Oxaliplatin Sensitivity.2024Frontiers in bioscience (Landmark edition)
  8. Single-cell dissection of the multicellular ecosystem and molecular features underlying microvascular invasion in HCC.2024Hepatology (Baltimore, Md.)免费全文
  9. RRP8, associated with immune infiltration, is a prospective therapeutic target in hepatocellular carcinoma.2024Journal of cancer research and clinical oncology免费全文
  10. Integrative transcriptome analysis identifies a crotonylation gene signature for predicting prognosis and drug sensitivity in hepatocellular carcinoma.2024Journal of cellular and molecular medicine免费全文
  11. A TiN-based nanophotosensitizer for enhanced photothermal therapy with the aid of ultrasound.2023Biochemical and biophysical research communications
  12. Alternative splicing of IRF3 plays an important role in the development of hepatocarcinoma.2023Epigenetics免费全文
  13. Characterization of prognostic value and immunological roles of RAB22A in hepatocellular carcinoma.2023Frontiers in immunology免费全文
  14. TMEM147 aggravates the progression of HCC by modulating cholesterol homeostasis, suppressing ferroptosis, and promoting the M2 polarization of tumor-associated macrophages.2023Journal of experimental & clinical cancer research : CR免费全文
  15. Triptonide inhibits growth and metastasis in HCC by suppressing EGFR/PI3K/AKT signaling.2023Neoplasma
  16. Targeting SLP2-mediated lipid metabolism reprograming restricts proliferation and metastasis of hepatocellular carcinoma and promotes sensitivity to Lenvatinib.2023Oncogene
  17. RNF125 attenuates hepatocellular carcinoma progression by downregulating SRSF1-ERK pathway.2023Oncogene
  18. Utility of mean platelet volume in differentiating intrahepatic cholangiocarcinoma from hepatocellular carcinoma.2022BMC gastroenterology免费全文
  19. Cytochrome B5 type A alleviates HCC metastasis via regulating STOML2 related autophagy and promoting sensitivity to ruxolitinib.2022Cell death & disease免费全文
  20. Long non-coding RNA TPTEP1 exerts inhibitory effects on hepatocellular carcinoma by impairing microRNA-454-3p-mediated DLG5 downregulation.2022Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  21. ANP32 Family as Diagnostic, Prognostic, and Therapeutic Biomarker Related to Immune Infiltrates in Hepatocellular Carcinoma.2022Disease markers免费全文
  22. Impact of concurrent splenectomy and esophagogastric devascularization on surgical outcomes of partial hepatectomy for hepatocellular carcinoma in patients with clinically significant portal hypertension: A multicenter propensity score matc2022European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  23. Identification of CFHR4 as a Potential Prognosis Biomarker Associated With lmmune Infiltrates in Hepatocellular Carcinoma.2022Frontiers in immunology免费全文
  24. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.2022Journal of experimental & clinical cancer research : CR免费全文
  25. Efficacy and safety of preoperative transarterial chemoembolization for hepatocellular carcinoma: a systematic review and meta-analysis.2022Scandinavian journal of gastroenterology
  26. Upregulation Mitochondrial Carrier 1 (MTCH1) Is Associated with Cell Proliferation, Invasion, and Migration of Liver Hepatocellular Carcinoma.2021BioMed research international免费全文
  27. TNF-α/NF-κB signaling epigenetically represses PSD4 transcription to promote alcohol-related hepatocellular carcinoma progression.2021Cancer medicine免费全文
  28. Postoperative morbidity adversely impacts long-term oncologic prognosis following hepatectomy for hepatocellular carcinoma: A multicenter observational study.2021European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  29. CXCR4 promotes gefitinib resistance of Huh7 cells by activating the c-Met signaling pathway.2021FEBS open bio免费全文
  30. The PGC1α/NRF1-MPC1 axis suppresses tumor progression and enhances the sensitivity to sorafenib/doxorubicin treatment in hepatocellular carcinoma.2021Free radical biology & medicine
  31. Homoharringtonine inhibits the progression of hepatocellular carcinoma by suppressing the PI3K/AKT/GSK3β/Slug signaling pathway.2021Neoplasma
中文论文(未计入)1
  1. [Research progress of FAPI PET/CT in the diagnosis of malignant liver tumors].2023Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
  1. The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects已终止NCT03236649研究中心III期2017-09 启动
  2. the Efficacy and Safety of Ginsenoside Rg3 Capsule in Prevention of Postoperative Recurrence of Hepatocellular Carcinoma已完成NCT01717066研究中心不分期2012-11 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

肺癌

Lung cancer

2021–2025 年中国大陆作者发表的 23,356 篇肺癌 PubMed 英文论文中,这家医院牵头了 25 篇,占 0.1%。

牵头论文
25
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 4420212022: 5520222023: 2220232024: 9920242025: 552025

哈尔滨有 4 家医院列在肺癌下全国有 251 家医院列在肺癌下

截至 2026年11月18日,ClinicalTrials.gov 上没有列出这家医院的肺癌开放试验。

这些数字背后的记录
论文中的科室影像/核医学科神经内科神经外科病理/检验科

这些论文过半是实验室或动物研究。

牵头的论文25
  1. MYBL2 regulates the expression of CENPF in lung adenocarcinoma and promotes tumor development and metastasis through AKT pathway activation.2025European journal of medical research免费全文
  2. CircRAPGEF5 Promotes LUAD by Mediating the HOXC6 Stability.2025FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  3. C-FOS promotes the formation of neutrophil extracellular traps and the recruitment of neutrophils in lung metastasis of triple-negative breast cancer.2025Journal of experimental & clinical cancer research : CR免费全文
  4. M2 macrophage-derived exosomes promote cell proliferation, migration and EMT of non-small cell lung cancer by secreting miR-155-5p.2025Molecular and cellular biochemistry
  5. Causal Associations Between Cystatin and Lung Cancer: A Two-Sample Mendelian Randomization Study.2025The clinical respiratory journal免费全文
  6. Non-invasively Discriminating the Pathological Subtypes of Non-small Cell Lung Cancer with Pretreatment 18F-FDG PET/CT Using Deep Learning.2024Academic radiology
  7. The clinical, molecular, and therapeutic implications of time from primary diagnosis to brain metastasis in lung and breast cancer patients.2024Cancer medicine免费全文
  8. SLC12A8 promotes the migration and invasion of non-small cell lung cancer (NSCLC) cells.2024General physiology and biophysics
  9. Impact of SARS-CoV-2 infection on immune cell cuproptosis in patients with lung adenocarcinoma via glutamine regulation.2024International immunopharmacology
  10. Exosomal miR-20b-5p Induces EMT and Enhances Progression in Non-Small Cell Lung Cancer Via TGFBR2 Downregulation.2024Journal of biochemical and molecular toxicology
  11. Learning curve for double-port video-assisted thoracoscopic lung segmentectomy: a propensity score matching study.2024Journal of cardiothoracic surgery免费全文
  12. Common immunological and prognostic features of lung and bladder cancer via smoking-related genes: PRR11 gene as potential immunotherapeutic target.2024Journal of cellular and molecular medicine免费全文
  13. Correlation between CT spectral quantitative parameters and expression levels of HIF-1α and ALX1 in non-small cell lung cancer.2024Medicine免费全文
  14. N6-methyladenosine-mediated LINC01087 promotes lung adenocarcinoma progression by regulating miR-514a-3p to upregulate centrosome protein 55.2024The Kaohsiung journal of medical sciences免费全文
  15. Targeting Pokemon is a novel strategy to suppress cancer aggressiveness of non-small cell lung cancer: Identification of Pokemon as ideal target for developing anti-NSCLC drugs.2023Archives of biochemistry and biophysics
  16. Association of plasma branched-chain amino acid with multiple cancers: A mendelian randomization analysis.2023Clinical nutrition (Edinburgh, Scotland)
  17. E3 ubiquitin-protein ligase 2 inhibits cell proliferation, migration, and invasion of non-small cell lung cancer through ubiquitination of Notch1.2022Acta histochemica
  18. A triple-classification for the evaluation of lung nodules manifesting as pure ground-glass sign: a CT-based radiomic analysis.2022BMC medical imaging免费全文
  19. A novel circ_MACF1/miR-942-5p/TGFBR2 axis regulates the functional behaviors and drug sensitivity in gefitinib-resistant non-small cell lung cancer cells.2022BMC pulmonary medicine免费全文
  20. Biological functions of nuclear-localized insulin receptor (IR) on A549 lung cancer cells.2022Endokrynologia Polska
  21. Prediction model based on 18F-FDG PET/CT radiomic features and clinical factors of EGFR mutations in lung adenocarcinoma.2022Neoplasma
  22. LncRNA MALAT1 aggravates oxygen-glucose deprivation/reoxygenation-induced neuronal endoplasmic reticulum stress and apoptosis via the miR-195a-5p/HMGA1 axis.2021Biological research免费全文
  23. Clinical significance of expression level of CX3CL1-CX3CR1 axis in bone metastasis of lung cancer.2021Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  24. GOLM1 predicts poor prognosis of patients with NSCLC and is associated with the proliferation and chemo-sensitivity of cisplatin in NSCLC cells: bioinformatics analysis and laboratory validation.2021Journal of bioenergetics and biomembranes
  25. Function and mechanism exploration of zinc finger protein 64 in lung adenocarcinoma cell growth and metastasis.2021Journal of receptor and signal transduction research
它在 ClinicalTrials.gov 上的全部试验(任何状态)3
  1. Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer已终止NCT06897579研究中心II期2025-04 启动
  2. A Multicentre Study on Features of the Gut Microbiota of Patients With Critical Chronic Diseases in China状态不明NCT05638269研究中心2022-03 启动
  3. A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer已终止NCT03745222研究中心III期2019-05 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胰腺癌

Pancreatic cancer

2021–2025 年中国大陆作者发表的 5,743 篇胰腺癌 PubMed 英文论文中,这家医院牵头了 23 篇,占 0.4%。

牵头论文
23
2021–2025 年
牵头试验
2
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 4420222023: 8820232024: 3320242025: 552025

哈尔滨有 3 家医院列在胰腺癌下全国有 192 家医院列在胰腺癌下

截至 2026年11月18日,ClinicalTrials.gov 上没有列出这家医院的胰腺癌开放试验。

这些数字背后的记录
论文中的科室普外/肝胆胰外科消化/肝病科影像/核医学科肿瘤内科

这些论文过半是实验室或动物研究。

牵头的论文23
  1. RNF187 neddylation in pancreatic cancer activates malignancy via IQGAP1-dependent actin cytoskeleton rearrangement.2026Oncogene免费全文
  2. Pancreatic Cancer in High-Income Asia-Pacific: A Population-Based Study.2025Cancer control : journal of the Moffitt Cancer Center免费全文
  3. The role of LncRNA-MANCR induced by HIF-1α drive the malignant progression of pancreatic cancer by targeting miRNA-494/SIRT1 signaling axis under hypoxic conditions.2025Cancer gene therapy
  4. The lncRNA ST18-AS1 suppresses pancreatic cancer progression by enhancing ST18 mRNA stability through anchoring FUS in the cytoplasm.2025Oncogene
  5. Alcohol-induced C/EBP β-driven VIRMA decreases oxidative stress and promotes pancreatic ductal adenocarcinoma growth and metastasis via the m6A/YTHDF2/SLC43A2 pathway.2025Oncogene
  6. TRPM4 expression predicts prognosis and modulates the immune microenvironment in pancreatic adenocarcinoma.2025Scientific reports免费全文
  7. Revealing a cancer-associated fibroblast-based risk signature for pancreatic adenocarcinoma through single-cell and bulk RNA-seq analysis.2024Aging免费全文
  8. LncRNA CCAT1 participates in pancreatic ductal adenocarcinoma progression by forming a positive feedback loop with c-Myc.2024Carcinogenesis
  9. Dual Starvations Induce Pyroptosis for Orthotopic Pancreatic Cancer Therapy through Simultaneous Deprivation of Glucose and Glutamine.2024Journal of the American Chemical Society
  10. Tumor Cell Derived Lnc-FSD2-31:1 Contributes to Cancer-Associated Fibroblasts Activation in Pancreatic Ductal Adenocarcinoma Progression through Extracellular Vesicles Cargo MiR-4736.2023Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  11. The application of single-cell sequencing in pancreatic neoplasm: analysis, diagnosis and treatment.2023British journal of cancer免费全文
  12. Clinical application of Al18F-NOTA-FAPI PET/CT in diagnosis and TNM staging of pancreatic adenocarcinoma, compared to 18F-FDG.2023Cancer imaging : the official publication of the International Cancer Imaging Society免费全文
  13. DUSP2 recruits CSNK2A1 to suppress AKT1-mediated apoptosis resistance under hypoxic microenvironment in pancreatic cancer.2023Cancer letters
  14. m6A regulators are differently expressed and correlated with immune response of pancreatic adenocarcinoma.2023Journal of cancer research and clinical oncology免费全文
  15. Caprin-1 influences autophagy-induced tumor growth and immune modulation in pancreatic cancer.2023Journal of translational medicine免费全文
  16. circEIF3I facilitates the recruitment of SMAD3 to early endosomes to promote TGF-β signalling pathway-mediated activation of MMPs in pancreatic cancer.2023Molecular cancer免费全文
  17. Identification of MIR600HG/hsa-miR-342-3p/ANLN network as a potential prognosis biomarker associated with lmmune infiltrates in pancreatic cancer.2023Scientific reports免费全文
  18. Diabetic Ferroptosis and Pancreatic Cancer: Foe or Friend?2022Antioxidants & redox signaling
  19. Positive feedback regulation of lncRNA TPT1-AS1 and ITGB3 promotes cell growth and metastasis in pancreatic cancer.2022Cancer science免费全文
  20. Identification of hub genes in chronic pancreatitis and analysis of association with pancreatic cancer via bioinformatic analysis.2022General physiology and biophysics
  21. Dictamnine inhibits pancreatic cancer cell growth and epithelial-mesenchymal transition by blocking the PI3K/AKT signaling pathway.2022Neoplasma
  22. Invadopodia: A potential target for pancreatic cancer therapy.2021Critical reviews in oncology/hematology
  23. Chinese expert consensus of image-guided irreversible electroporation for pancreatic cancer.2021Journal of cancer research and therapeutics
中文论文(未计入)1
  1. [Current status and controversy of neoadjuvant therapy in pancreatic cancer].2021Zhonghua yi xue za zhi
它在 ClinicalTrials.gov 上的全部试验(任何状态)4
  1. The Mechanism of Enhancing the Anti-tumor Effects of CAR-T on PC by Gut Microbiota Regulation状态不明NCT04203459牵头方2019-10 启动
  2. Evaluate the Safety and Efficacy of CAR-T in the Treatment of Pancreatic Cancer.状态不明NCT03267173牵头方早期I期2017-06 启动
  3. A Multicentre Study on Features of the Gut Microbiota of Patients With Critical Chronic Diseases in China状态不明NCT05638269研究中心2022-03 启动
  4. Laparoscopic vs Open Pancreatectomy for Body and Tail Pancreatic Cancer状态不明NCT03792932研究中心不分期2019-02 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

乳腺癌

Breast cancer

2021–2025 年中国大陆作者发表的 16,974 篇乳腺癌 PubMed 英文论文中,这家医院牵头了 23 篇,占 0.1%。

牵头论文
23
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 5520212022: 1120222023: 4420232024: 7720242025: 662025

哈尔滨有 4 家医院列在乳腺癌下全国有 219 家医院列在乳腺癌下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer
    分期
    III期
    开始
    2025-07
    发布
    登记号
    NCT07047365

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 44 家列出的医院为研究中心兰州、北京、南京、南充、南宁、南昌、合肥、哈尔滨、唐山、天津、太原、宁波、安阳、徐州、成都、新乡、昆明、沈阳、泸州、洛阳、济南、海口、深圳、温州、潍坊、石家庄、蚌埠、襄阳、西宁、西安、贵阳、郑州、重庆、长春、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室普外/肝胆胰外科影像/核医学科肿瘤内科神经外科
牵头的论文23
  1. A survival analysis of T1 stage breast cancer and nomogram development: based on the SEER database.2025Clinics (Sao Paulo, Brazil)免费全文
  2. Survival analysis of metachronous bilateral ectopic breast cancer utilizing the SEER database and the pioneering construction of a nomogram model.2025European journal of medical research免费全文
  3. Immune-based molecular subtyping of triple-negative breast cancer via SNF-CC and functional validation of key immune-associated genes.2025Functional & integrative genomics
  4. Expression and prognostic impact of hypoxia- and immune escape-related genes in triple-negative breast cancer: A comprehensive analysis.2025International immunopharmacology
  5. C-FOS promotes the formation of neutrophil extracellular traps and the recruitment of neutrophils in lung metastasis of triple-negative breast cancer.2025Journal of experimental & clinical cancer research : CR免费全文
  6. Nomogram construction and survival analysis in T3N0M0 breast cancer: a SEER population-based analysis.2025Scientific reports免费全文
  7. A novel nomogram and survival analysis for different lymph node status in breast cancer based on the SEER database.2024Breast cancer (Tokyo, Japan)免费全文
  8. Circulating lipids, lipid-lowering drug targets, and breast cancer risk: Comprehensive evidence from Mendelian randomization and summary data-based Mendelian randomization.2024Cancer causes & control : CCC
  9. Nomograms for predicting recurrence of HER2-positive breast cancer with different HR status based on ultrasound and clinicopathological characteristics.2024Cancer medicine免费全文
  10. The clinical, molecular, and therapeutic implications of time from primary diagnosis to brain metastasis in lung and breast cancer patients.2024Cancer medicine免费全文
  11. CircRNA hsa_circ_0003528/miR-215 is considered a potential target for predictive prognosis and therapy for triple-negative breast cancer.2024Molecular biology reports
  12. Long non‑coding RNA DANCR aggravates breast cancer through the miR‑34c/E2F1 feedback loop.2024Molecular medicine reports免费全文
  13. Unveiling the mysteries of HER2-low expression in breast cancer: pathological response, prognosis, and expression level alterations.2024World journal of surgical oncology免费全文
  14. Association of plasma branched-chain amino acid with multiple cancers: A mendelian randomization analysis.2023Clinical nutrition (Edinburgh, Scotland)
  15. Silencing MFHAS1 Induces Pyroptosis via the JNK-activated NF-κB/Caspase1/ GSDMD Signal Axis in Breast Cancer.2023Current pharmaceutical design
  16. ING1 inhibits Twist1 expression to block EMT and is antagonized by the HDAC inhibitor vorinostat.2023European journal of cell biology
  17. Clinicopathological analysis and prognostic treatment study of angiosarcoma of the breast: a SEER population-based analysis.2023World journal of surgical oncology免费全文
  18. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.2022Journal of experimental & clinical cancer research : CR免费全文
  19. Analysis of prognostic risk factors in 3427 patients with invasive ductal carcinoma of breast: Results based on the SEER database.2021Asian journal of surgery
  20. NDV-D90 inhibits 17β-estradiol-mediated resistance to apoptosis by differentially modulating classic and nonclassic estrogen receptors in breast cancer cells.2021Journal of cellular biochemistry
  21. The nomogram based on the 6-lncRNA model can promote the prognosis prediction of patients with breast invasive carcinoma.2021Scientific reports免费全文
  22. Phosphatidylserine-exposing tumor-derived microparticles exacerbate coagulation and cancer cell transendothelial migration in triple-negative breast cancer.2021Theranostics免费全文
  23. Long-term oncologic safety of immediate reconstructive surgery in patients with invasive breast cancer: a retrospective matched-cohort study.2021World journal of surgical oncology免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
  1. Intestinal Microbiota of Breast Cancer Patients Undergoing Chemotherapy状态不明NCT04138979牵头方2019-09 启动
  2. TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer正在招募NCT07047365研究中心III期2025-07 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胶质瘤

Glioma

2021–2025 年中国大陆作者发表的 7,081 篇胶质瘤 PubMed 英文论文中,这家医院牵头了 35 篇,占 0.5%。

牵头论文
35
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 7720212022: 8820222023: 6620232024: 4420242025: 10102025

哈尔滨有 4 家医院列在胶质瘤下全国有 187 家医院列在胶质瘤下

截至 2026年11月18日,ClinicalTrials.gov 上没有列出这家医院的胶质瘤开放试验。

这些数字背后的记录
论文中的科室神经外科影像/核医学科病理/检验科神经内科

这些论文过半是实验室或动物研究。

牵头的论文35
  1. Hemorrhagic and ischemic risks of anti-VEGF therapies in glioblastoma.2025Cancer gene therapy
  2. Bioinformatics Analysis Screening and Identification of Key Biomarkers and Drug Targets in Human Glioblastoma.2025Current medicinal chemistry免费全文
  3. Research landscape of glioma and inflammation over the past two decades.2025Frontiers in immunology免费全文
  4. HSPA5-mediated glioma hypoxia tolerance promotes M2 macrophage polarization under hypoxic microenvironment.2025International immunopharmacology
  5. Bone morphogenetic protein 1 as a macromolecular pan-cancer biomarker modulating the immune microenvironment and malignant phenotypes in glioblastoma.2025International journal of biological macromolecules
  6. Integrative spatial multi-omics identifies the TEK receptor tyrosine kinase as a central biomacromolecule of endothelial-immune interactions in glioblastoma.2025International journal of biological macromolecules
  7. Ubiquitin-conjugating enzyme E2S decreases the sensitivity of glioblastoma cells to temozolomide by upregulating PGAM1 via the interaction with OTUB2.2025International journal of biological macromolecules
  8. Hypoxia-Inducible Factor-1α Regulates BNIP3-Dependent Mitophagy and Mediates Metabolic Reprogramming Through Histone Lysine Lactylation Modification to Affect Glioma Proliferation and Invasion.2025Journal of biochemical and molecular toxicology
  9. Ho(III)-coordination Complex: Fluorescence Performances and Combined with Captopril-Hydrogels against Glioma.2025Journal of fluorescence
  10. Investigating the Aidi injection mechanism for low-grade glioma based on the network pharmacology approach, The Cancer Genome Atlas (TCGA), and molecular docking technology.2025Medicine免费全文
  11. Integrated analysis of bulk and single-cell RNA sequencing reveals the impact of nicotinamide and tryptophan metabolism on glioma prognosis and immunotherapy sensitivity.2024BMC neurology免费全文
  12. UBE2S facilitates glioblastoma progression through activation of the NF-κB pathway via attenuating K11-linked ubiquitination of AKIP1.2024International journal of biological macromolecules
  13. Etomidate inhibits tumor growth of glioblastoma by regulating M1 macrophage polarization.2024Metabolic brain disease
  14. Armored bicistronic CAR T cells with dominant-negative TGF-β receptor II to overcome resistance in glioblastoma.2024Molecular therapy : the journal of the American Society of Gene Therapy免费全文
  15. Immunostimulant In Situ Fibrin Gel for Post-operative Glioblastoma Treatment by Macrophage Reprogramming and Photo-Chemo-Immunotherapy.2023ACS applied materials & interfaces
  16. Proteogenomic characterization of ferroptosis regulators reveals therapeutic potential in glioblastoma.2023BMC cancer免费全文
  17. Evaluating glioma-associated microRNA by complementation on a biological nanosensor.2023Biotechnology and applied biochemistry
  18. LncRNA as potential biomarker and therapeutic target in glioma.2023Molecular biology reports
  19. Prevalence, risk factors and prognostic value of anxiety and depression in recurrent glioma patients.2023Psychology, health & medicine
  20. Identification of DNA Damage Repair Gene Signature as a Novel Prognostic Marker in Glioblastoma Multiforme.2023World neurosurgery
  21. Oncogenic Forkhead box D3 antisense RNA 1 promotes cell survival and confers temozolomide resistance in glioblastoma cells through the miR-128-3p/WEE1 G2 checkpoint kinase axis.2022Bioengineered免费全文
  22. The Mechanisms of Current Platinum Anticancer Drug Resistance in the Glioma.2022Current pharmaceutical design免费全文
  23. Pan-cancer analysis of ASB3 and the potential clinical implications for immune microenvironment of glioblastoma multiforme.2022Frontiers in immunology免费全文
  24. CCL2-targeted ginkgolic acid exerts anti-glioblastoma effects by inhibiting the JAK3-STAT1/PI3K-AKT signaling pathway.2022Life sciences
  25. Chelerythrine inhibits the progression of glioblastoma by suppressing the TGFB1-ERK1/2/Smad2/3-Snail/ZEB1 signaling pathway.2022Life sciences
  26. Locally secreted BiTEs complement CAR T cells by enhancing killing of antigen heterogeneous solid tumors.2022Molecular therapy : the journal of the American Society of Gene Therapy免费全文
  27. Identification of Prognostic Biomarkers for Glioblastoma Based on Transcriptome and Proteome Association Analysis.2022Technology in cancer research & treatment免费全文
  28. Simvastatin Inhibits Tumor Growth and Migration by Mediating Caspase-1-Dependent Pyroptosis in Glioblastoma Multiforme.2022World neurosurgery
  29. IL-24 inhibits the malignancy of human glioblastoma cells via destabilization of Zeb1.2021Biological chemistry
  30. Interfering with hyaluronic acid metabolism suppresses glioma cell proliferation by regulating autophagy.2021Cell death & disease免费全文
  31. Double-targeting CDCA8 and E2F1 inhibits the growth and migration of malignant glioma.2021Cell death & disease免费全文
  32. TMEM2 Combined with IDH and 1p19q in Refining Molecular Subtypes for Predicting Survival of Patients with Glioma.2021DNA and cell biology
  33. MSH6 Aggravates the Hypoxic Microenvironment via Regulating HIF1A to Promote the Metastasis of Glioblastoma Multiforme.2021DNA and cell biology
  34. Reminiscence therapy-based care program for reducing anxiety and depression in glioma survivors: A randomized controlled trial.2021MedicineRCT免费全文
  35. Clinical Value of TXNDC12 Combined With IDH and 1p19q as Biomarkers for Prognosis of Glioma.2021Pathology oncology research : POR免费全文

打开 PubMed 检索ClinicalTrials.gov

癌症

肝母细胞瘤

Hepatoblastoma

2021–2025 年没有牵头肝母细胞瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

哈尔滨有 1 家医院列在肝母细胞瘤下全国有 86 家医院列在肝母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肝母细胞瘤开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

癌症

视网膜母细胞瘤

Retinoblastoma

2021–2025 年中国大陆作者发表的 301 篇视网膜母细胞瘤 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.7%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 0020222023: 0020232024: 0020242025: 002025

哈尔滨有 2 家医院列在视网膜母细胞瘤下全国有 176 家医院列在视网膜母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的视网膜母细胞瘤开放试验。

这些数字背后的记录
论文中的科室眼科/神经眼科

打开 PubMed 检索ClinicalTrials.gov

癌症

骨肉瘤

Osteosarcoma

2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 21 篇,占 0.9%。

牵头论文
21
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 4420212022: 5520222023: 3320232024: 4420242025: 552025

哈尔滨有 6 家医院列在骨肉瘤下全国有 570 家医院列在骨肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。

这些数字背后的记录
论文中的科室影像/核医学科神经内科

这些论文过半是实验室或动物研究。

牵头的论文21
  1. Heterogeneous c-Met Activation in Osteosarcoma Dictates Synergistic Vulnerability to Combined c-Met Inhibition and Methotrexate Therapy.2025Anticancer research
  2. Harmine exerts anticancer effects through the ROS/p38 axis to induce autophagy and apoptosis in osteosarcoma.2025Bioorganic chemistry
  3. Extraskeletal Ewing Sarcoma of the Abdominopelvic Cavity Revealed by 18 F-FDG PET/CT.2025Clinical nuclear medicine
  4. A strategy for challenging tumorous bone regeneration by borosilicate bioactive glass boosting moderate magnetic hyperthermia.2025Nature communications免费全文
  5. Antitumor effects of cannabidiol (CBD) on osteosarcoma by targeting TNF-α/NF-κB/CCL5 signaling axis.2025Phytomedicine : international journal of phytotherapy and phytopharmacology
  6. NAT10 mediated ac4C acetylation driven m6A modification via involvement of YTHDC1-LDHA/PFKM regulates glycolysis and promotes osteosarcoma.2024Cell communication and signaling : CCS免费全文
  7. A novel hypoxia- and lactate metabolism-related prognostic signature to characterize the immune landscape and predict immunotherapy response in osteosarcoma.2024Frontiers in immunology免费全文
  8. M7G modification of FTH1 and pri-miR-26a regulates ferroptosis and chemotherapy resistance in osteosarcoma.2024Oncogene
  9. Vitamin C enhances the sensitivity of osteosarcoma to arsenic trioxide via inhibiting aerobic glycolysis.2024Toxicology and applied pharmacology
  10. Integration of single-cell sequencing and bulk expression data reveals chemokine signaling pathway in proliferating cells is associated with the survival outcome of osteosarcoma.2023BMC medical genomics免费全文
  11. RING finger gene 180 inhibits osteosarcoma progression through regulating chromobox homolog 4 ubiquitination.2023Cell cycle (Georgetown, Tex.)免费全文
  12. PINK1 regulates apoptosis of osteosarcoma as the target gene of cisplatin.2023Journal of orthopaedic surgery and research免费全文
  13. Bevacizumab attenuates osteosarcoma angiogenesis by suppressing MIAT encapsulated by serum-derived extracellular vesicles and facilitating miR-613-mediated GPR158 inhibition.2022Cell death & disease免费全文
  14. The Subcellular Localization of IncRNA FAM230B in Osteosarcoma and Its Interaction with Early miR-203.2022Critical reviews in eukaryotic gene expression
  15. LncRNA BACE1-AS promotes the progression of osteosarcoma through miR-762/SOX7 axis.2022Molecular biology reports
  16. Hydroxygenkwanin suppresses proliferation, invasion and migration of osteosarcoma cells via the miR‑320a/SOX9 axis.2022Molecular medicine reports免费全文
  17. Involvement of miR-769-5p/Retinoic Acid Receptor Responder 1 Axis in the Progression of Osteosarcoma: Characterization of Potential Therapeutic Targets.2022Pharmacology
  18. Accurate Identification and Early Diagnosis of Osteosarcoma through CRISPR-Cas12a-Based Average Telomerase Activity Detection.2021ACS synthetic biology
  19. Profiles of immune cell infiltration and immune-related genes in the tumor microenvironment of osteosarcoma cancer.2021BMC cancer免费全文
  20. NPR3, transcriptionally regulated by POU2F1, inhibits osteosarcoma cell growth through blocking the PI3K/AKT pathway.2021Cellular signalling
  21. Long non‑coding RNA H19 regulates LASP1 expression in osteosarcoma by competitively binding to miR‑29a‑3p.2021Oncology reports免费全文
早期论文(2016–2020 年)26
  1. Camptothecin induced DDX5 degradation increased the camptothecin resistance of osteosarcoma.2020Experimental cell research
  2. Downregulation of lncRNA SNHG12 reversed IGF1R-induced osteosarcoma metastasis and proliferation by targeting miR-195-5p.2020Gene
  3. Circular RNA LARP4 correlates with decreased Enneking stage, better histological response, and prolonged survival profiles, and it elevates chemosensitivity to cisplatin and doxorubicin via sponging microRNA-424 in osteosarcoma.2020Journal of clinical laboratory analysis
  4. Construction and Validation of Nomograms for Predicting the Prognosis of Juvenile Osteosarcoma: A Real-World Analysis in the SEER Database.2020Technology in cancer research & treatment
  5. NFIL3 Acts as a Nuclear Factor to Increase Osteosarcoma Progression.2019BioMed research international
  6. Albumin-bioinspired iridium oxide nanoplatform with high photothermal conversion efficiency for synergistic chemo-photothermal of osteosarcoma.2019Drug delivery
  7. Long noncoding RNA NORAD regulates cancer cell proliferation and migration in human osteosarcoma by endogenously competing with miR-199a-3p.2019IUBMB life
  8. Synergistic anti-tumor effects of arsenic trioxide and blue LED irradiation on human osteosarcoma.2019International journal of biological sciences
  9. SIRT1-ZEB1-positive feedback promotes epithelial-mesenchymal transition process and metastasis of osteosarcoma.2019Journal of cellular biochemistry
  10. Non‑covalent proteasome inhibitor PI‑1840 induces apoptosis and autophagy in osteosarcoma cells.2019Oncology reports
  11. miR-590-3p is a novel microRNA which suppresses osteosarcoma progression by targeting SOX9.2018Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  12. Chimaphilin inhibits human osteosarcoma cell invasion and metastasis through suppressing the TGF-β1-induced epithelial-to-mesenchymal transition markers via PI-3K/Akt, ERK1/2, and Smad signaling pathways.2018Canadian journal of physiology and pharmacology
  13. Targeting the FOXM1-regulated long noncoding RNA TUG1 in osteosarcoma.2018Cancer science
  14. Construction and analysis of a ceRNA‑ceRNA network reveals two potential prognostic modules regulated by hsa‑miR‑335‑5p in osteosarcoma.2018International journal of molecular medicine
  15. MicroRNA-129-5p suppresses cell proliferation, migration and invasion via targeting ROCK1 in osteosarcoma.2018Molecular medicine reports
  16. Deoxyelephantopin Induces Reactive Oxygen Species-Mediated Apoptosis and Autophagy in Human Osteosarcoma Cells.2017Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology
  17. A novel mechanism of mTORC1-mediated serine/glycine metabolism in osteosarcoma development.2017Cellular signalling
  18. MicroRNA-492 overexpression exerts suppressive effects on the progression of osteosarcoma by targeting PAK7.2017International journal of molecular medicine
  19. Berberine affects osteosarcoma via downregulating the caspase-1/IL-1β signaling axis.2017Oncology reports
  20. Circular RNA hsa-circ-0016347 promotes proliferation, invasion and metastasis of osteosarcoma cells.2017Oncotarget
  21. Single nucleotide polymorphism of hsa-miR-124a affects risk and prognosis of osteosarcoma.2016Cancer biomarkers : section A of Disease markers
  22. A single nucleotide polymorphism in the 3'-untranslated region of the KRAS gene disrupts the interaction with let-7a and enhances the metastatic potential of osteosarcoma cells.2016International journal of molecular medicine
  23. Identification of CD20, ECM, and ITGA as Biomarkers for Osteosarcoma by Integrating Transcriptome Analysis.2016Medical science monitor : international medical journal of experimental and clinical research
  24. Relationship Between P15 Gene Mutation and Formation and Metastasis of Malignant Osteosarcoma.2016Medical science monitor : international medical journal of experimental and clinical research
  25. Long noncoding RNA FGFR3-AS1 promotes osteosarcoma growth through regulating its natural antisense transcript FGFR3.2016Molecular biology reports
  26. MicroRNA-503 represses epithelial-mesenchymal transition and inhibits metastasis of osteosarcoma by targeting c-myb.2016Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine

打开 PubMed 检索ClinicalTrials.gov

癌症

胃肠道间质瘤

Gastrointestinal stromal tumour

2021–2025 年没有牵头胃肠道间质瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

哈尔滨有 5 家医院列在胃肠道间质瘤下全国有 240 家医院列在胃肠道间质瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的胃肠道间质瘤开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

癌症

神经母细胞瘤

Neuroblastoma

2021–2025 年中国大陆作者发表的 1,132 篇神经母细胞瘤 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.3%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 1120232024: 1120242025: 002025

哈尔滨有 7 家医院列在神经母细胞瘤下全国有 321 家医院列在神经母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的神经母细胞瘤开放试验。

这些数字背后的记录
论文中的科室神经内科

打开 PubMed 检索ClinicalTrials.gov

癌症

尤文肉瘤

Ewing sarcoma

2021–2025 年中国大陆作者发表的 163 篇尤文肉瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.6%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

哈尔滨有 1 家医院列在尤文肉瘤下全国有 134 家医院列在尤文肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的尤文肉瘤开放试验。

这些数字背后的记录
论文中的科室影像/核医学科

打开 PubMed 检索ClinicalTrials.gov

血液疾病

多发性骨髓瘤

Multiple myeloma

2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 4 篇,占 0.2%。

牵头论文
4
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 0020222023: 0020232024: 1120242025: 002025

哈尔滨有 3 家医院列在多发性骨髓瘤下全国有 175 家医院列在多发性骨髓瘤下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Risk Stratification and MRD-driven Maintenance for MM After ASCT
    分期
    不分期
    开始
    2024-12
    发布
    登记号
    NCT06697483

    年龄 18 岁 至 未注明(登记的条件)

    牵头:北京大学人民医院;另有 2 家列出的医院为研究中心北京、哈尔滨

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题干细胞移植复发与耐药

打开 PubMed 检索ClinicalTrials.gov

血液疾病

B 细胞急性淋巴细胞白血病

B-cell acute lymphoblastic leukaemia

2021–2025 年中国大陆作者发表的 225 篇B 细胞急性淋巴细胞白血病 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.9%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 112025

哈尔滨有 1 家医院列在B 细胞急性淋巴细胞白血病下全国有 88 家医院列在B 细胞急性淋巴细胞白血病下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的B 细胞急性淋巴细胞白血病开放试验。

这些数字背后的记录
研究主题抗体与靶向药物费城染色体与遗传学CAR-T 与细胞治疗
论文中的科室肿瘤内科

打开 PubMed 检索ClinicalTrials.gov

血液疾病

淋巴瘤

Lymphoma

2021–2025 年中国大陆作者发表的 3,830 篇淋巴瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.03%。

牵头论文
1
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

哈尔滨有 3 家医院列在淋巴瘤下全国有 199 家医院列在淋巴瘤下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Prospective Study of Low-dose Decitabine Combined With COP Regimen in the Treatment of Relapsed and Refractory DLBCL
    分期
    未注明
    开始
    2018-03
    发布
    登记号
    NCT03494296

    年龄 18 岁 至 未注明(登记的条件)

    牵头:哈尔滨医科大学附属第一医院哈尔滨

  2. 正在招募
    A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
    分期
    III期
    开始
    2025-09
    发布
    登记号
    NCT06973187

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 24 家列出的医院为研究中心上海、兰州、北京、南宁、南昌、南通、哈尔滨、大连、太原、宁波、徐州、成都、武汉、沈阳、泸州、温州、石家庄、福州、苏州、西宁、西安、郑州、长春、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

血液疾病

血栓性血小板减少性紫癜

Thrombotic thrombocytopenic purpura

2021–2025 年中国大陆作者发表的 64 篇血栓性血小板减少性紫癜 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.6%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

哈尔滨有 1 家医院列在血栓性血小板减少性紫癜下全国有 59 家医院列在血栓性血小板减少性紫癜下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的血栓性血小板减少性紫癜开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

烟雾病

Moyamoya disease

2021–2025 年中国大陆作者发表的 356 篇烟雾病 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.6%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 2220242025: 002025

哈尔滨有 1 家医院列在烟雾病下全国有 47 家医院列在烟雾病下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Registry of Multicenter Brain-Heart Comorbidity in China
    分期
    未注明
    开始
    2012-01
    发布
    登记号
    NCT05961748

    年龄 18 岁 至 未注明(登记的条件)

    牵头:首都医科大学附属北京天坛医院;另有 4 家列出的医院为研究中心上海、北京、哈尔滨、郑州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题遗传血管重建手术影像与脑血流
论文中的科室神经内科神经外科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

冠心病

Coronary heart disease

2021–2025 年中国大陆作者发表的 5,119 篇冠心病 PubMed 英文论文中,这家医院牵头了 8 篇,占 0.2%。

牵头论文
8
2021–2025 年
牵头试验
5
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
3
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 1120222023: 3320232024: 3320242025: 002025

哈尔滨有 3 家医院列在冠心病下全国有 231 家医院列在冠心病下

这家医院参与的开放试验 3

依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Phase 2b Clinical Trial of YN001 in Adults With Coronary Atherosclerosis
    分期
    II期
    开始
    2026-07
    发布
    登记号
    NCT07521007

    年龄 18 岁 至 80 岁(登记的条件)

    牵头方不是列出的医院;另有 17 家列出的医院为研究中心上海、兰州、北京、合肥、哈尔滨、天津、广州、成都、杭州、武汉、福州、苏州、西安、长春、长沙

  2. 正在招募
    Efficacy and Safety Trials of Yangxinshi Tablets in the Treatment of Patients With Coronary Heart Disease Complicated by Cardiac Dysfunction
    分期
    IV期
    开始
    2025-11
    发布
    登记号
    NCT07110415

    年龄 40 岁 至 80 岁(登记的条件)

    牵头方不是列出的医院;另有 41 家列出的医院为研究中心上海、兰州、北京、南京、南宁、哈尔滨、大庆、大连、天津、宁波、广州、张家口、成都、杭州、汕头、沈阳、济南、深圳、湖州、烟台、珠海、石家庄、西安、贵阳、重庆、银川、长春、青岛

  3. 正在招募
    Registry of Multicenter Brain-Heart Comorbidity in China
    分期
    未注明
    开始
    2012-01
    发布
    登记号
    NCT05961748

    年龄 18 岁 至 未注明(登记的条件)

    牵头:首都医科大学附属北京天坛医院;另有 8 家列出的医院为研究中心上海、北京、哈尔滨、福州、郑州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
牵头的论文8
  1. Application effect of task-oriented multi-dimensional nursing intervention in patients with coronary atherosclerotic heart disease and concurrent hypertension.2024African health sciences免费全文
  2. Association between Troponin Elevation and Decreased Myocardial Blood Flow Reserve in Patients without Obstructive Coronary Artery Disease.2024Cardiology免费全文
  3. Prognostic value of computed tomography-derived fractional flow reserve in patients with diabetes mellitus and unstable angina.2024Cardiovascular diabetology免费全文
  4. Predicting coronary artery disease by carotid color doppler ultrasonography.2023European review for medical and pharmacological sciences
  5. Association of marine PUFAs intakes with cardiovascular disease, all-cause mortality, and cardiovascular mortality in American adult male patients with dyslipidemia: the U.S. National Health and Nutrition Examination Survey, 2001 to 2016.2023Nutrition journal免费全文
  6. Characteristics of coronary artery ectasia and accompanying plaques: an optical coherence tomography study.2023The international journal of cardiovascular imaging免费全文
  7. Influence of obstructive sleep apnoea on coronary artery disease in a Chinese population.2022The Journal of international medical research免费全文
  8. Efficacy and safety of different ticagrelor regimens versus clopidogrel in patients with coronary artery disease: a retrospective multicenter study (SUPERIOR).2021Platelets
中文论文(未计入)2
  1. [Study on the procoagulant characteristics of microparticles in acute myocardial infarction].2024Zhonghua wei zhong bing ji jiu yi xue
  2. [Update on the role and evaluation index of perivascular adipose tissue in coronary atherosclerosis].2021Zhonghua xin xue guan bing za zhi
它在 ClinicalTrials.gov 上的全部试验(任何状态)14
  1. Effect of FFRCT-angio in Functional Diagnosis of Coronary Artery Stenosis状态不明NCT04493086牵头方2020-10 启动
  2. Ticagrelor and Clopidogrel on Platelet Effects in Chinese Patients With Stable Coronary Artery Disease已完成NCT04001894牵头方IV期2019-07 启动
  3. Lipid-lowering Effects of Gefarnate in Statin-treated Coronary Heart Disease Patients With Residual Hypertriglyceridemia状态不明NCT03610321牵头方II/III期2019-09 启动
  4. Efficacy and Safety of Low-dose Ticagrelor已完成NCT03381742牵头方II/III期2017-12 启动
  5. Effects of Different Doses of Ticagrelor on Platelet Aggregation and Endothelial Function in Diabetic Patients With Stable Coronary Artery Disease状态不明NCT02889549牵头方II/III期2016-08 启动
  6. A Phase 2b Clinical Trial of YN001 in Adults With Coronary Atherosclerosis正在招募NCT07521007研究中心II期2026-07 启动
  7. Efficacy and Safety Trials of Yangxinshi Tablets in the Treatment of Patients With Coronary Heart Disease Complicated by Cardiac Dysfunction正在招募NCT07110415研究中心IV期2025-11 启动
  8. Registry of Multicenter Brain-Heart Comorbidity in China正在招募NCT05961748研究中心2012-01 启动
  9. Efficacy and Safety of Colchicine After PCI进行中,不再招募NCT06472908研究中心III期2024-07 启动
  10. Phitys I™ Percutaneous Left Ventricular Assist System Study状态不明NCT06357026研究中心不分期2024-04 启动
  11. Risk Evaluation by COronary CTA and Artificial IntelliGence Based fuNctIonal analyZing tEchniques - II状态不明NCT05856110研究中心2023-07 启动
  12. CorVad Percutaneous Ventricular Assist System Study状态不明NCT06198998研究中心不分期2023-10 启动
  13. Risk Evaluation by COronary CTA and Artificial intelliGence Based fuNctIonal analyZing tEchniques - I状态不明NCT05884008研究中心2023-05 启动
  14. Sensor-equipped Ultrathin Pressure Microcatheter Versus Pressure Wire for Physiological Measurements已完成NCT05417763研究中心2022-02 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

脊柱侧弯

Scoliosis

2021–2025 年中国大陆作者发表的 925 篇脊柱侧弯 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.2%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 1120232024: 0020242025: 002025

哈尔滨有 1 家医院列在脊柱侧弯下全国有 107 家医院列在脊柱侧弯下

截至 2026年11月18日,ClinicalTrials.gov 上没有列出这家医院的脊柱侧弯开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

特发性肺纤维化

Idiopathic pulmonary fibrosis

2021–2025 年中国大陆作者发表的 989 篇特发性肺纤维化 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.2%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 222025

哈尔滨有 3 家医院列在特发性肺纤维化下全国有 288 家医院列在特发性肺纤维化下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的特发性肺纤维化开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

肌萎缩侧索硬化症

Amyotrophic lateral sclerosis

2021–2025 年中国大陆作者发表的 779 篇肌萎缩侧索硬化症 PubMed 英文论文中,这家医院牵头了 11 篇,占 1.4%。

牵头论文
11
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 1120232024: 3320242025: 662025

哈尔滨有 3 家医院列在肌萎缩侧索硬化症下全国有 182 家医院列在肌萎缩侧索硬化症下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肌萎缩侧索硬化症开放试验。

这些数字背后的记录
论文中的科室神经内科

这些论文过半是实验室或动物研究。

牵头的论文11
  1. COMM domain containing 4 inhibits hephaestin and ferroportin to enhance neuronal ferroptosis by disturbing the Cu-Fe balance in amyotrophic lateral sclerosis.2025Brain research
  2. Inhibition of Salt-Inducible Kinase 2 Protects Motor Neurons From Degeneration in ALS by Activating Autophagic Flux and Enhancing mTORC1 Activity.2025CNS neuroscience & therapeutics免费全文
  3. Integrative genomics and functional immunology reveal Clostridia species as modulators of neuroinflammation in amyotrophic lateral sclerosis.2025Inflammation research : official journal of the European Histamine Research Society ... [et al.]
  4. Fisetin Attenuates Mutant SOD1 Aggregation in Amyotrophic Lateral Sclerosis via Nrf2-Mediated Autophagy Activation.2025Journal of molecular neuroscience : MN
  5. DAPK1 induces motor neuron apoptosis in hSOD1G93A-linked amyotrophic lateral sclerosis via regulating the Xiap/JNK pathway.2025Molecular and cellular neurosciences
  6. Multi-omics framework integrating genetics microbiome and immunity for understanding motor neuron degeneration pathogenesis.2025NPJ biofilms and microbiomes免费全文
  7. RBM5 induces motor neuron apoptosis in hSOD1G93A-related amyotrophic lateral sclerosis by inhibiting Rac1/AKT pathways.2024Brain research bulletin
  8. Roflupram alleviates autophagy defects and reduces mutant hSOD1-induced motor neuron damage in cell and mouse models of amyotrophic lateral sclerosis.2024Neuropharmacology
  9. BRD7 regulates cellular senescence and apoptosis in ALS by modulating p21 expression and p53 mitochondrial translocation respectively.2024Neuroscience
  10. SPY1 inhibits neuronal ferroptosis in amyotrophic lateral sclerosis by reducing lipid peroxidation through regulation of GCH1 and TFR1.2023Cell death and differentiation免费全文
  11. Diphenyl diselenide protects motor neurons through inhibition of microglia-mediated inflammatory injury in amyotrophic lateral sclerosis.2021Pharmacological research
早期论文(2016–2020 年)8
  1. Wild-type p53-induced phosphatase 1 down-regulation promotes apoptosis by activating the DNA damage-response pathway in amyotrophic lateral sclerosis.2020Neurobiology of disease
  2. Neuroprotection by urate on the mutant hSOD1-related cellular and Drosophila models of amyotrophic lateral sclerosis: Implication for GSH synthesis via activating Akt/GSK3β/Nrf2/GCLC pathways.2019Brain research bulletin
  3. Spy1, a unique cell cycle regulator, alters viability in ALS motor neurons and cell lines in response to mutant SOD1-induced DNA damage.2019DNA repair
  4. γ-Oryzanol mitigates oxidative stress and prevents mutant SOD1-Related neurotoxicity in Drosophila and cell models of amyotrophic lateral sclerosis.2019Neuropharmacology
  5. α-Lipoic acid attenuates oxidative stress and neurotoxicity via the ERK/Akt-dependent pathway in the mutant hSOD1 related Drosophila model and the NSC34 cell line of amyotrophic lateral sclerosis.2018Brain research bulletin
  6. Fisetin Exerts Antioxidant and Neuroprotective Effects in Multiple Mutant hSOD1 Models of Amyotrophic Lateral Sclerosis by Activating ERK.2018Neuroscience
  7. Downregulation of Homer1b/c in SOD1 G93A Models of ALS: A Novel Mechanism of Neuroprotective Effect of Lithium and Valproic Acid.2016International journal of molecular sciences
  8. Comparative Analysis of VOCs in Exhaled Breath of Amyotrophic Lateral Sclerosis and Cervical Spondylotic Myelopathy Patients.2016Scientific reports

打开 PubMed 检索ClinicalTrials.gov

其他疾病

白塞病

Behçet disease

2021–2025 年中国大陆作者发表的 245 篇白塞病 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.4%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

哈尔滨有 2 家医院列在白塞病下全国有 139 家医院列在白塞病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的白塞病开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

IgA 肾病

IgA nephropathy

2021–2025 年中国大陆作者发表的 736 篇IgA 肾病 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.3%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 112025

哈尔滨有 4 家医院列在IgA 肾病下全国有 300 家医院列在IgA 肾病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的IgA 肾病开放试验。

这些数字背后的记录
论文中的科室肾内科
牵头的论文2
  1. Effects of disease severity-based nursing intervention on immune function and IFN-γ, IL-6, and TNF-α for children with IgA vasculitis nephritis.2025Naunyn-Schmiedeberg's archives of pharmacology
  2. Epidemiology and risk factors for progression in Chinese patients with IgA nephropathy.2021Medicina clinica
早期论文(2016–2020 年)1
  1. Increased phosphatidylserine-exposing microparticles and their originating cells are associated with the coagulation process in patients with IgA nephropathy.2016Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

打开 PubMed 检索ClinicalTrials.gov

其他疾病

先天性巨结肠

Hirschsprung disease

2021–2025 年中国大陆作者发表的 161 篇先天性巨结肠 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.6%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

哈尔滨有 1 家医院列在先天性巨结肠下全国有 76 家医院列在先天性巨结肠下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的先天性巨结肠开放试验。

这些数字背后的记录
论文中的科室儿科神经内科

打开 PubMed 检索ClinicalTrials.gov

联系这家医院

出示给工作人员或司机的院名卡

哈尔滨医科大学附属第一医院

First Affiliated Hospital of Harbin Medical University

哈尔滨

大医院往往有多个院区,出发前请先向医院确认院区。

中英对照的咨询信

填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。

医院通常需要的资料

  • 主治医生近期的病情总结或信件
  • 病理报告
  • 影像检查(CT、MRI、PET)及报告,尽量附影像文件
  • 已接受的治疗及时间
  • 目前用药

下一步建议

与主治医生沟通可将本页分享给主治医生,一同评估该团队的研究方向是否相关。
确认团队现状论文发表通常滞后数月,医生也可能调动。请在医院官网查询相关科室。
直接联系医院请通过医院官方公布的渠道联系。医院不向我们支付任何费用;是否接诊由医院决定。

这些数字从哪里来

论文

2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义

试验

ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。

编号与其他名称

ROR
First Affiliated Hospital of Harbin Medical College

提出更正下载数据